Quanterix (QTRX) Stock Price, News & Analysis

Company Overview

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company’s core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers. In addition, Quanterix offers the SP-X Imaging and Analysis System for multiplexed protein detection, along with a range of reagent kits, calibrators and consumables. These products address applications in neurodegenerative disease, oncology, immunology, infectious disease and cardiovascular research, supporting both preclinical studies and clinical trial workflows.

Founded in 2007 and headquartered in Billerica, Massachusetts, Quanterix went public on the Nasdaq under the ticker QTRX in 2017. The company serves a global customer base that includes academic institutions, biopharmaceutical companies and contract research organizations. Quanterix maintains commercial and support offices in North America, Europe and the Asia-Pacific region to facilitate instrument deployment, training and technical service.

Leadership is led by President and Chief Executive Officer Kevin Hrusovsky, under whose direction Quanterix has expanded its technology applications and strategic collaborations. The company continues to invest in research and development to enhance assay menus, improve automation and extend digital immunoassay capabilities into new areas of translational research and clinical diagnostics.

Key Stats

• Today's Range: $2.61 to $2.80
• 50-Day Range: $2.51 to $4.76
• 52-Week Range: $2.39 to $8.77
• Volume: 814,980 shs
• Average Volume: 1.49 million shs
• Market Capitalization: $126.73 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Reduce

Quanterix Stock Analysis - MarketRank™

Quanterix scored higher than 34% of companies evaluated by MarketBeat, and ranked 705th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Reduce

Consensus Rating

Quanterix has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Quanterix has a consensus price target of $4.00, representing about 48.7% upside from its current price of $2.69.

Amount of Analyst Coverage

Quanterix has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Quanterix are expected to grow in the coming year, from ($0.97) to ($0.81) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Quanterix is -1.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Quanterix is -1.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Quanterix has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.91% of the float of Quanterix has been sold short.

Short Interest Ratio / Days to Cover

Quanterix has a short interest ratio ("days to cover") of 4.49.

Change versus previous month

Short interest in Quanterix has recently increased by 6.84%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Quanterix does not currently pay a dividend.

Dividend Growth

Quanterix does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for QTRX on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Quanterix insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.50% of the stock of Quanterix is held by insiders.

Percentage Held by Institutions

86.48% of the stock of Quanterix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/06/2026
• Today: 5/22/2026
• Next Earnings (Estimated): 8/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: NASDAQ:QTRX
• CIK: 1503274
• Web: www.quanterix.com
• Phone: (617) 301-9400
• Fax: N/A
• Employees: 460
• Year Founded: 2007

Price Target and Rating

• Average Price Target for Quanterix: $4.00
• High Price Target: $4.00
• Low Price Target: $4.00
• Potential Upside/Downside: +48.7%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.36)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$107.15 million
• Net Margins: -71.86%
• Pretax Margin: -73.39%
• Return on Equity: -23.92%
• Return on Assets: -17.66%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.72
• Quick Ratio: 2.70

Sales & Book Value

• Annual Sales: $138.90 million
• Price / Sales: 0.91
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.99 per share
• Price / Book: 0.45

Miscellaneous

• Outstanding Shares: 47,110,000
• Free Float: 46,399,000
• Market Cap: $126.73 million
• Optionable: Optionable
• Beta: 1.15